Historic Step for Alzheimer’s Care in Canada: CDA-AMC Recognizes Clinical Value of LEQEMBI® (lecanemab) and Recommends Public Coverage for Early Alzheimer’s Disease

Canada’s Drug Agency recognizes the clinical value of LEQEMBI ^® in slowing Alzheimer’s progression and helping keep patients in earlier stages of disease for longer

MISSISSAUGA, ON and TORONTO, July 16, 2026 /CNW/ — Eisai Limited (“Eisai”) and Biogen Canada Inc. are honoured to be one of the first countries in the world to receive a positive Health Technology Assessment recommendation for public reimbursement, as announced today by Canada’s Drug Agency (CDA-AMC). This decision demonstrates that CDA-AMC recognizes the significant unmet need for a disease modifying treatment for early Alzheimer’s disease (AD). It is clear that CDA-AMC listened to the extensive and consistent feedback from clinical experts, patients and stakeholders as well as the review of new 48-month data which demonstrates the benefits of continuous treatment with LEQEMBI. This represents a historic milestone, supports equitable access for patients, and brings eligible Canadians one step closer to accessing the first treatment approved in Canada that targets the underlying biology of Alzheimer’s disease (AD) and may help keep patients in the earlier stages of disease for longer.^1,2

The positive recommendation overturns the CDA-AMC’s previous draft recommendation, incorporating the evidence and stating that “lecanemab is likely to provide meaningful benefit in addressing some unmet needs in early Alzheimer’s disease such as delaying progression”.³ One of the key takeaways from the CDA-AMC review of the 48-month data analysis was that it suggests “increasing treatment effect compared with earlier time points (18 and 36 months)”,³ meaning that the treatment benefits of LEQEMBI increase over time.

People living in the earliest stage of AD, also known as mild cognitive impairment (MCI) is the phase prior to dementia, when individuals are usually still functioning independently and playing an active role in daily life, such as caring for grandchildren, volunteering or even acting as caregiver to their own partners.⁴ 

“We welcome CDA-AMC’s recommendation, which underscores the significant value LEQEMBI brings to patients and highlights the urgent need for treatments that, for the first time, modify the course of early AD,” said Pat Forsythe, Vice President & General Manager, Eisai Limited. “This recommendation reflects a shared commitment to improving Alzheimer’s care and offers new hope to patients and families across most of the country. It also reflects the strong support of Canadians, whose voices continue to highlight the importance of expanding equitable access to new treatment options for those living with this disease.”

AD is the most common form of dementia, accounting for 60 to 80% of all cases.⁵ In Canada, more than 771,000 people are living with dementia — a number projected to rise to approximately 1 million by 2030.⁶ 

“We are heartened by CDA-AMC’s recommendation to reimburse lecanemab on public drug plans, which reflects input from Alzheimer Societies and partners across the country and marks a significant milestone for Canadians affected by Alzheimer’s disease,” said Christina Scicluna, CEO, Alzheimer Society of Canada. “This is a time of hope in the Alzheimer’s community, with scientific advances creating new opportunities to slow decline and help people maintain their independence for longer. Today’s decision is an important step forward and reinforces the urgent need for equitable access to a system that supports Canadians throughout their Alzheimer’s journey, which includes sustained investments in navigation, diagnosis, treatment, and community supports.”

“What a huge relief that CDA-AMC has listened and understood the value of preserving function and quality of life at early stages of AD, such that individuals can remain active and engaged in activities that matter to them and to their families,” said Dr. Sharon Cohen, Neurologist and Medical Director of Toronto Memory Program. “We are now one step closer to more equitable access to a treatment that slows AD. Canadians will appreciate this milestone.”

“As we strive to deliver equitable care in Canada, this decision represents a meaningful step forward for Canadians living with AD and for the health system,” said Dr. Jo-Anne Clarke, Medical Director of the North-East Specialized Geriatric Centre. “Many individuals in the early stages of AD remain highly functional, continue to work and contribute meaningfully to their communities, and in many cases support their own families in caregiving. Equitable public access in northern and rural communities across Canada, to treatments like LEQEMBI, offers meaningful and much-needed hope to patients for extending this period of independence, and the opportunity to create more consistent care pathways, ensuring more Canadians can benefit from timely diagnosis and treatment.”

The draft recommendation for LEQEMBI is currently open and accepting stakeholder feedback until July 30, 2026. Feedback can be submitted by visiting cda-amc.ca/lecanemab.

Eisai remains deeply committed to a patient-centered approach in Alzheimer’s care and is dedicated to working closely with healthcare systems and stakeholders to ensure that eligible individuals living with early AD can access LEQEMBI as quickly as possible. Eisai will continue to collaborate with provinces and territories to support effective and timely implementation of public coverage across Canada.

Notes to Editors

1. About lecanemab (generic name, brand name: LEQEMBI^®)
   Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).
   
   Lecanemab has been approved in 53 countries and regions including Japan, the United States, China, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulatory review in 6 countries. Following the initial phase with treatment every two weeks for 18 months, intravenous (IV) maintenance dosing with treatment every four weeks was approved in 8 countries including the U.S., China, the UK, and others, and applications have been filed in 12 countries and regions. The U.S. FDA approved Eisai’s Biologics License Application (BLA) for subcutaneous maintenance dosing with LEQEMBI IQLIK in August 2025. A Supplemental Biologics License Application (sBLA) for initiation treatment was accepted in January 2026 and granted Priority Review. The sBLA has been assigned an extended Prescription Drug User Fee Act (PDUFA) action date of August 24, 2026. In November 2025, an application for a subcutaneous injectable formulation in Japan was submitted. In January 2026, the Biologics License Application (BLA) for the subcutaneous formulation was accepted in China. In December 2025, Lecanemab (IV) has been included in the “Commercial Insurance Innovative Drug List”, recently introduced by the National Healthcare Security Administration (NHSA) of China.
   
   Since July 2020 the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer’s Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.
   
   
2. About the Collaboration between Eisai and Biogen for AD
   Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.
   
   
3. About the Collaboration between Eisai and BioArctic for AD
   Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.
   
   
4. About Eisai Canada
   Eisai Canada was established in 2011, one of more than 40 subsidiaries of global, industry-leader Eisai Co., Ltd. Rooted in Eisai’s focus on delivering human health care (hhc), Eisai Canada is on a mission to support all Canadians by creating solutions in areas where significant medical challenges and treatment gaps persist. Eisai Canada’s commitment to innovative R&D and open collaboration across lines of business, industry, language and culture has resulted in an industry-leading pipeline in Neurology and Oncology. Powered by the strength of our collaborations, we discover and deliver medicines that matter to people living with Cancer, Epilepsy, Insomnia and Alzheimer’s Disease.
   
   
5. About Eisai Co., Ltd.
   Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
   
   In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.
   
   For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai. Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (global and U.S.), LinkedIn (for global, U.S. and EMEA) and Facebook (global).
   
   
6. About Biogen and Biogen Canada Inc.
   Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
   
   Biogen has been proudly serving Canadian patients for more than 25 years. For information about Biogen Canada, please visit www.biogen.ca.

Biogen Safe Harbor

This news release contains forward-looking statements, including about the potential clinical effects of lecanemab (LEQEMBI); the potential benefits, safety and efficacy of LEQEMBI; potential regulatory discussions, submissions and approvals and the timing thereof, including Canada’s Drug Agency’s decision to recommend LEQEMBI for public reimbursement in Canada; the treatment of Alzheimer’s disease; the anticipated benefits and potential of Biogen’s collaboration arrangements with Eisai; the potential of Biogen’s commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would” or the negative of these words or other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements.

These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to differ materially from those stated or implied in this document, including, among others, uncertainty of our long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans, prospects and timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways; our ability to effectively implement our corporate strategy; difficulties in obtaining and maintaining adequate coverage, pricing, and reimbursement for our products; the drivers for growing our business, including our dependence on collaborators and other third parties for the development, regulatory approval, and commercialization of products and other aspects of our business, which are outside of our full control; risks related to commercialization of biosimilars, which is subject to such risks related to our reliance on third-parties, intellectual property, competitive and market challenges and regulatory compliance; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; and the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at www.sec.gov.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our subsequent reports on Form 10-Q. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

Biogen Digital Media Disclosure

From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen-) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.

Media Contacts: 

Eisai Limited (Canada)
Ashley Concessio
+1-437-451-4519
Ashley_Concessio@eisai.com 

Eisai Inc. (U.S.)
Libby Holman
+1-201-753-1945
Libby_Holman@eisai.com

Biogen Canada Inc.
Karla Fuentes Arellano
+1-416-717-5152
can-communicationscanada@biogen.com 

SOURCE Eisai Limited